BioLife Solutions Inc
NASDAQ:BLFS

Watchlist Manager
BioLife Solutions Inc Logo
BioLife Solutions Inc
NASDAQ:BLFS
Watchlist
Price: 20.85 USD -1.6%
Market Cap: $1B

BioLife Solutions Inc
Stock-Based Compensation

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

BioLife Solutions Inc
Stock-Based Compensation Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Stock-Based Compensation CAGR 3Y CAGR 5Y CAGR 10Y
BioLife Solutions Inc
NASDAQ:BLFS
Stock-Based Compensation
$23m
CAGR 3-Years
-3%
CAGR 5-Years
31%
CAGR 10-Years
46%
Haemonetics Corp
NYSE:HAE
Stock-Based Compensation
$31.6m
CAGR 3-Years
10%
CAGR 5-Years
6%
CAGR 10-Years
12%
ICU Medical Inc
NASDAQ:ICUI
Stock-Based Compensation
$55.8m
CAGR 3-Years
16%
CAGR 5-Years
18%
CAGR 10-Years
16%
Align Technology Inc
NASDAQ:ALGN
Stock-Based Compensation
$185.9m
CAGR 3-Years
12%
CAGR 5-Years
14%
CAGR 10-Years
13%
Lantheus Holdings Inc
NASDAQ:LNTH
Stock-Based Compensation
$85.6m
CAGR 3-Years
43%
CAGR 5-Years
43%
CAGR 10-Years
46%
Merit Medical Systems Inc
NASDAQ:MMSI
Stock-Based Compensation
$43.5m
CAGR 3-Years
34%
CAGR 5-Years
25%
CAGR 10-Years
35%
No Stocks Found

BioLife Solutions Inc
Glance View

Market Cap
1B USD
Industry
Health Care

BioLife Solutions Inc., hailing from Bothell, Washington, tells a story of innovation within the niche yet critical biopreservation industry. Emerging as a vital player for cell and gene therapy developers, BioLife Solutions specializes in creating hypothermic storage and transport media tailored for fragile biologic material. Their cornerstone products, like CryoStor and HypoThermosol, are formulated to prolong the shelf-life and viability of cells, tissues, and organs during storage and transportation. These solutions are designed for ultra-cold environments, ensuring the cellular integrity required by biopharmaceutical companies and research institutions engaged in the leading-edge development of regenerative medicine. The company's business model is centered around both direct sales and strategic partnerships. By deeply embedding its proprietary preservation media into clinical-grade processes, BioLife Solutions establishes itself as an integral component of its clients' supply chains. In doing so, the company generates revenue not just from initial sales of its products, but from ongoing usage as therapies move through development pipelines into mainstream clinical applications. Additionally, their diversification into automated thawing devices and personalized medicine services bolster recurring revenue streams, positioning them strategically in an expanding market driven by technological advancements in cellular therapies. Thus, BioLife Solutions stands firmly at the confluence of innovation and necessity, drawing strength from its strategic foresight and commitment to preserving the future of medicine.

BLFS Intrinsic Value
10.84 USD
Overvaluation 48%
Intrinsic Value
Price $20.85

See Also

What is BioLife Solutions Inc's Stock-Based Compensation?
Stock-Based Compensation
23m USD

Based on the financial report for Dec 31, 2025, BioLife Solutions Inc's Stock-Based Compensation amounts to 23m USD.

What is BioLife Solutions Inc's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 10Y
46%

Over the last year, the Stock-Based Compensation growth was -26%. The average annual Stock-Based Compensation growth rates for BioLife Solutions Inc have been -3% over the past three years , 31% over the past five years , and 46% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett